Event

Jürgen Behr

M.D.
Medizinische Klinik und Poliklinik V, University of Munich (LMU) and Asklepios Klinik München-Gautin

Manuel Quaresma

PharmD
Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim am Rhein, and Center for Interstitial and Rare ;Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim am Rhein, and Center for Interstitial

Martin R. J. Kolb

M.D., Ph.D.
Firestone Institute for Respiratory Health, McMaster University;Firestone Institute for Respiratory Health, The Research Institute of St. Joe's Hamilton, St.Joseph';Mc Master Univ;McMaster Univ;McMast

Ganesh Raghu

M.D.
University of Washington

Sven Yannik Schnaidt

MSc
Boehringer Ingelheim Pharma GmbH & Co. KG

Fernando J. Martinez

MD, MS
Cornell University;New York-Presbyterian Hospital/Weill Cornell Medical Center;Weill Cornell Medical College;Weill Cornell Medical College, Cornell University;Weill Cornell Medicine

Susanne Stowasser

M.D.
Boehringer Ingelheim Pharma GmbH & Co. KG

Luca Richeldi

MD, PhD
Catholic University of the Sacred Heart;Università Cattolica del Sacro Cuore, Fondazione Policlinico A. Gemelli

Athol Wells

M.D.
Interstitial Lung Disease Unit, Royal Brompton Hospital;Royal Brompton and Harefield NHS Foundation Trust, and National Heart and Lung Institute, Imperial C;Royal Brompton Hospital

INSTAGE: A Randomized Trial of Nintedanib Plus Sildenafil Versus Nintedanib Alone in Patients with Idiopathic Pulmonary Fibrosis (IPF) and Advanced Lung Function Impairment